Biologic scaffold for prevention of pulmonary fibrosis

Patent metadata

Field	Value
Publication number	US-9084722-B2
Application number	US-200913132708-A
Country	US
Kind code	B2
Filing date	Dec 4, 2009
Priority date	Dec 5, 2008
Publication date	Jul 21, 2015
Grant date	Jul 21, 2015

Abstract

Provided herein are methods of preventing, lessening or treating pulmonary fibrosis in a subject. The methods comprise delivering an amount of a powdered extracellular matrix (ECM)-derived material to the respiratory system of the subject effective to prevent, lessen or treat pulmonary fibrosis in a subject. Also provided is an apparatus for delivering the powdered ECM-derived material to a subject.

First claim

We claim:

1. A method of reducing interstitial lung disease in a subject in need thereof, comprising:
administering via the subject's airway a composition comprising a devitalized, decellularized layer of extracellular matrix material that is delaminated from one or more layers of a devitalized epithelial tissue in an amount effective to reduce interstitial lung disease in the subject.

2. The method of claim 1 , in which the airway delivery system is a metered dose inhaler.

3. The method of claim 1 , in which the airway delivery system is a metered-dose inhaler and the composition comprises a propellant.

4. The method of claim 1 , in which the composition is a dry powder.

5. The method of claim 4 , in which the powdered composition has a maximum particle size of 250 μM.

6. The method of claim 4 , in which the powdered composition has a maximum particle size of 75 μM.

7. The method of claim 1 , in which the composition is a liquid.

8. The method of claim 1 , wherein the interstitial lung disease is associated with silicosis; asbestosis; berylliosis; hypersensitivity pneumonitis; drug induced interstitial lung disease, connective tissue disease, systemic sclerosis, dermatomyositis, systemic lupus erythematosus, rheumatoid arthritis; infection, atypical pneumonia, pneumocystis pneumonia (PCP), tuberculosis; idiopathic interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, Hamman-Rich syndrome, a malignancy, or lymphangitic carcinomatosis.

9. The method of claim 1 , wherein between 10 μg and 1000 mg of the composition is delivered to the subject.

10. The method of claim 1 , in which the composition comprises epithelial basement membrane.

11. The method of claim 1 , in which the composition comprises tunica propria.

12. The method of claim 11 , in which the composition further comprises submucosa.

13. The method of claim 1 , in which the composition is administered to a subject prior to or after chemotherapy or radiotherapy.

14. The method of claim 1 , in which the composition is administered to a subject exposed to a chemical agent.

15. The method of claim 1 , in which the composition is solubilized.

16. The method of claim 1 , wherein the administering of the composition to the subject's airway is prior to, during or after exposure to a fibrosis-inducing event.

17. The method of claim 1 , wherein the administering of the composition to the subject's airway is prior to, during or after exposure to chemotherapy.

Assignees

• Gilbert Thomas
• Manni Michelle
• Oury Tim D
• Univ Pittsburgh—Of The Commonwealth System Of Higher Education

Inventors

• Gilbert Thomas
• Manni Michelle
• Oury Tim D

Classifications

• A61M11/00

  Sprayers or atomisers specially adapted for therapeutic purposes (in general B05B; {aerosol containers B65D83/14}) · CPC title

• A61K9/0075 Primary

  for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles · CPC title

• A61M16/04

  Tracheal tubes (catheters in general A61M25/00) · CPC title

• A61K9/008

  comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI] · CPC title

• A61K9/0078

  for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions · CPC title